CCM
WGS icon

Chilton Capital Management’s GeneDx Holdings WGS Stock Holding History

Chilton Capital Management’s Portfolio WGS Stock Details WGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8
Closed -$1.04K – 754
2025
Q4 		$1.04K Buy
+8
New +$1.1K ﹤0.01% 588

Other funds holding WGS

CM
Corvex Management New York $3.27B AUM 38.53% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Chilton Capital Management's WGS Position: Q1 2026 in Review

Chilton Capital Management sold out of GeneDx Holdings (WGS) in Q1 2026, closing a stake of 8 shares — an estimated $1.04K sold.

Chilton Capital Management first reported a position in WGS in Q4 2025 and held it in 1 quarter. The position peaked at $1.04K in Q4 2025. 240 funds tracked by Wall St. Rank hold WGS as of Q1 2026.

  • Chilton Capital Management reported no remaining GeneDx Holdings position as of Q1 2026 after selling out during the quarter.
  • Chilton Capital Management sold 8 GeneDx Holdings shares in Q1 2026, an estimated $1.04K.
  • Chilton Capital Management first reported a position in GeneDx Holdings in Q4 2025 and held it in 1 quarter.
  • Chilton Capital Management's GeneDx Holdings position peaked at $1.04K in Q4 2025.
  • 240 funds tracked by Wall St. Rank held GeneDx Holdings as of Q1 2026.

Based on Chilton Capital Management's 13F filing for Q1 2026, filed 11 May 2026.